sellModerate cluster of 4
Aaron G.L. Fletcher sold $225k of ACTU
director, owner at ACTUATE THERAPEUTICS, INC.. 24,999 shares at an average of $9.00, traded Aug 14, 2024, filed Aug 14, 2024.
Warning score
42Value
$225k
24,999 shares
Holdings after
131,248
-8% from before
From 52-week low
+6%
low $8.61, close $9.15
From 52-week high
0%
high $9.15, as of Aug 14, 2024
Score components
- +15RoleDirector
- +12Trade size$225k at market
- 0Share of holdings soldSold 8.2% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
ACTUOct 12, 2026 · close 0.64
Since filing Aug 14, 2024: -93.0%SPY +46.8% · excess -139.8%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-089822, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Clinical Opportunity Fund, LP | +884,427 | - | - | 884,427 | Aug 14, 2024 |
| Aug 14, 2024 | POpen-market purchase Common Stockindirect: Directly held by Bios Clinical Opportunity Fund, LP | +375,000 | $8.00 | $3.0M | 1,259,427 | Aug 14, 2024 |
| Aug 14, 2024 | POpen-market purchase Common Stockindirect: Directly held by Bios 2024 Co-Invest, LP | +125,000 | $8.00 | $1.0M | 125,000 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund I, LP | +525,797 | - | - | 525,797 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund I QP, LP | +307,538 | - | - | 307,538 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II, LP | +141,457 | - | - | 141,457 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II QP, LP | +462,073 | - | - | 462,073 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II NT, LP | +61,857 | - | - | 61,857 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest I, LP | +153,702 | - | - | 153,702 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II, LP | +54,032 | - | - | 195,489 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II QP, LP | +176,499 | - | - | 638,572 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II NT, LP | +23,628 | - | - | 85,485 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest I, LP | +147,047 | - | - | 300,749 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II, LP | +101,900 | - | - | 297,389 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II QP, LP | +332,867 | - | - | 971,439 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund II NT, LP | +44,559 | - | - | 130,044 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund III, LP | +309,589 | - | - | 309,589 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund III QP, LP | +2,022,029 | - | - | 2,022,029 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund III NT, LP | +326,547 | - | - | 326,547 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest II, LP | +2,094,650 | - | - | 2,094,650 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund III, LP | +74,202 | - | - | 383,791 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund III QP, LP | +484,638 | - | - | 2,506,667 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Fund III NT, LP | +78,267 | - | - | 404,814 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest III, LP | +573,394 | - | - | 573,394 | Aug 14, 2024 |
| Aug 14, 2024 | XIn-the-money exercise Common Stockindirect: Directly held by Bios Fund II, LP | +8,068 | $5.27 | $43k | 305,457 | Aug 14, 2024 |
| Aug 14, 2024 | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II, LP | -5,314 | $9.00 | $48k | 300,143 | Aug 14, 2024 |
| Aug 14, 2024 | XIn-the-money exercise Common Stockindirect: Directly held by Bios Fund II QP, LP | +26,355 | $5.27 | $139k | 997,794 | Aug 14, 2024 |
| Aug 14, 2024 | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II QP, LP | -17,361 | $9.00 | $156k | 980,433 | Aug 14, 2024 |
| Aug 14, 2024 | XIn-the-money exercise Common Stockindirect: Directly held by Bios Fund II NT, LP | +3,528 | $5.27 | $19k | 133,572 | Aug 14, 2024 |
| Aug 14, 2024 | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II NT, LP | -2,324 | $9.00 | $21k | 131,248 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Convertible Notederivativeindirect: Directly held by Bios Clinical Opportunity Fund, LP | -884,427 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund I, LP | -525,797 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund I QP, LP | -307,538 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II, LP | -141,457 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II QP, LP | -462,073 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II NT, LP | -61,857 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Actuate Co-Invest I, LP | -153,702 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II, LP | -54,032 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II QP, LP | -176,499 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II NT, LP | -23,628 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Actuate Co-Invest I, LP | -147,047 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-3 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II, LP | -101,900 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-3 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II QP, LP | -332,867 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-3 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II NT, LP | -44,559 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-4 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III, LP | -309,589 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-4 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III QP, LP | -2,022,029 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-4 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III NT, LP | -326,547 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series B-4 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Actuate Co-Invest II, LP | -2,094,650 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series C Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III, LP | -74,202 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series C Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III QP, LP | -484,638 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series C Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III NT, LP | -78,267 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | CConversion Series C Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Actuate Co-Invest III, LP | -573,394 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: Directly held by Bios Fund II, LP | -8,068 | $0.00 | $0 | 0 | Aug 14, 2024 |
| Aug 14, 2024 | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: Directly held by Bios Fund II QP, LP | -26,355 | $0.00 | $0 | 0 | Aug 14, 2024 |
| Aug 14, 2024 | XIn-the-money exercise Warrant (Right to Buy)derivativeindirect: Directly held by Bios Fund II NT, LP | -3,528 | $0.00 | $0 | 0 | Aug 14, 2024 |
| Aug 12, 2024 | AGrant or award Stock Optionsderivativeindirect: Directly held by Aaron G.L. Fletcher | +15,000 | $0.00 | $0 | 15,000 | Aug 14, 2024 |
Related signals
Other insiders at ACTUATE THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | ACTUsell ACTUATE THERAPEUTICS, INC. | Todd S Thomson director, owner | $1.6M 280,000 shares | -24% | |
| 58Moderate | ACTUATE THERAPEUTICS, INC. | Aaron G.L. Fletcher director, owner | $500k 71,428 shares | +57% | |
| 58Moderate | ACTUATE THERAPEUTICS, INC. | Leslie W. Kreis director, owner | $500k 71,428 shares | +57% | |
| 58Moderate | ACTUATE THERAPEUTICS, INC. | Bios Equity COF, LP director, owner | $500k 71,428 shares | +57% | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | Cavu Advisors, LLC director, owner | $200k 24,999 shares | -8% | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | Aaron G.L. Fletcher director, owner | $200k 24,999 shares | -8% | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | Bios Equity COF, LP director, owner | $200k 24,999 shares | -8% | |
| 41Moderate | ACTUATE THERAPEUTICS, INC. | Todd S Thomson director, other | $150k 18,750 shares | -2% | |
| 75Notable | ACTUATE THERAPEUTICS, INC. | Cavu Advisors, LLC director, owner | $4.0M 500,000 shares | +57% | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | Cavu Advisors, LLC director, owner | $225k 24,999 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.